Cherwell Opens Expanded Redipor Prepared Media Manufacturing Facility
![](/46/pdcnewsitem/03/34/10/DObM48EYICDSz0v.jpg)
Cherwell Laboratories, manufacturer of Redipor prepared microbiological media, has completed an expansion programme at its Bicester-based facility. Initiated in response to a significant increase in demand, Cherwell has doubled the size of its cleanroom manufacturing suite and recruited additional staff to support the higher production capacity. Cherwell is renowned for offering a flexible supply of quality prepared media products, and the expanded facility ensures increasing demand in the UK and mainland Europe can be accommodated.
Cherwell’s continuing growth is partly fuelled by the development of export sales — up 55% in the past 2 years — and the appointment of further European distributors for the Redipor range. Already supported in Italy, Ireland, Poland and Slovenia, Cherwell has recently signed distributor agreements with AcefeSA in Spain and Dorte Egelund in Denmark. The company has carefully selected partners with the capability to deliver the same quality of service enjoyed by its UK customers.
The company has increased its UK market share through a dedication to customer service and the ability to deliver bespoke prepared media solutions. Many customers are switching to the convenience of Redipor pre-prepared media rather than making their own onsite. Increased pressure by regulators for more environmental monitoring has also led to overall growth in the prepared media market. Notably, demand for Redipor Barrier pack products, for use in isolators where vaporised hydrogen peroxide (VHP) is present, has grown, reflecting the increased use of VHP technology for sterilisation procedures.
Andy Whittard, Managing Director, Cherwell Laboratories commented: “This investment in facilities and capabilities is a clear indication of our commitment to developing our position as a leading supplier of prepared media. Recent market research shows our customers value not just the quality of our products, but increasingly our service and support. Most importantly, we are consistently delivering what our customers want.”
He added: “By developing our export markets through carefully selected partners, we aim to continue growing our UK-based production in a controlled manner, keeping excellent service and the customer at the core of what we do.”
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance